Updated: Apellis vows to be transparent about eye inflammation tied to Syfovre, but questions remain

Amber Tong

Paul Schloesser

Associate Editor

Apellis Pharmaceuticals still can’t pinpoint exactly what’s behind the rare cases of eye inflammation that’s been reported in patients taking its geographic atrophy drug Syfovre …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Apellis vows to be transparent about eye inflammation tied to Syfovre, but questions remain

Amber Tong

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

Maze's ALS spinout Trace Neuroscience raises $101M for ALS and neuro work

Pfizer looking to sell hospital drugs unit — reports

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

'Expertise is a real thing': FDA commissioner warns of political risk to agency

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Up­dat­ed: Apel­lis vows to be trans­par­ent about eye in­flam­ma­tion tied to Syfovre, but ques­tions re­main

Associate Editor

Sign up to read this article for free.

Updated: Apellis vows to be transparent about eye inflammation tied to Syfovre, but questions remain